Theralase targets up to C$5 million in brokered private placement at C$0.24 per unit

• Theralase launched a brokered LIFE private placement of units at C$ 0.24 to raise C$ 3 million to C$ 5 million.
• Each unit includes 1 common share, 1 warrant exercisable at C$ 0.32 until May 20, 2031.
• Proceeds earmarked for GLP toxicology work supporting clinical development of Rutherrin intravenous cancer program, Ruvidar topical cold sore program, working capital.
• Research Capital to act as sole agent; offering size can increase by up to 15% via an over-allotment option.
• Closing targeted for Aug. 24, 2026, subject to TSXV approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theralase Technologies Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608101715NEWSFILECNPR____20260810_309076_1) on August 10, 2026, and is solely responsible for the information contained therein.